权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Systemic Inflammation in Microphysiological Models of Muscle and Vascular Disease

肌肉和血管疾病微生理模型中的全身炎症

基本信息

批准号：
10471015
负责人：
George A Truskey
金额：
$ 7.33万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10471015
关键词：
Affect Animal Model Anti-Inflammatory Agents Antibodies Arteries Atherosclerosis Attenuated Autoimmune Diseases Biological Markers Biological Models Biomechanics Blood Vessels CRISPR/Cas technology Cardiac Cardiovascular Diseases Cell Proliferation Cells Cholesterol Chronic Chronic Disease Clinical Clustered Regularly Interspaced Short Palindromic Repeats Development Disease Disease Progression Disease model Drug Modelings Endothelial Cells Endothelium Environment Event Exercise Exposure to Feedback Foam Cells Functional disorder Gene Expression Genes Genetic Variation Goals Heart Human Immune Immune response In Vitro Individual Inflammation Inflammatory Inflammatory Response Interleukin 6 Receptor Interleukin-6 Laboratories Lipid-Laden Macrophage Lipids Lipoproteins Liquid substance Low-Density Lipoproteins Mediating Modeling Muscle Muscle function Muscular Atrophy Mutation Myocardium Myopathy Pathology Pattern Perfusion Pharmaceutical Preparations Pharmacotherapy Phase Phenotype Population Process Proprotein Convertases Proteins Rheumatoid Arthritis Risk Role Severities Severity of illness Single Nucleotide Polymorphism Site Skeletal Muscle Smooth Muscle Myocytes Structure Subtilisins Symptoms System Technology Testing Therapeutic Intervention Therapeutic exercise Tissue Engineering Tissues Variant Vascular Diseases base cardiovascular disorder risk clinically relevant cytokine disease phenotype drug development drug discovery drug testing effectiveness testing endothelial dysfunction gain of function mutation genetic variant human disease improved in vitro Model in vivo induced pluripotent stem cell joint inflammation loss of function loss of function mutation macrophage microphysiology system novel therapeutics population based progression marker repaired response shear stress spatial temporal variation systemic inflammatory response therapeutic target

项目摘要

ABSTRACT The initiation and progression of atherosclerosis is influenced by systemic inflammation and individuals suffering from autoimmune diseases, such as rheumatoid arthritis, have increased risk of developing cardiovascular diseases. Likewise, chronic and systemic inflammation in rheumatoid arthritis induces muscle wasting and loss of function. Therapies that reduce inflammation effectively treat rheumatoid arthritis and have the potential to reduce the severity of cardiovascular disease. To overcome limitations of animal models replicating some key disease phenotypes, but not the underlying mechanisms, we established functional human microphysiological systems (hMPS) for healthy human skeletal and cardiac muscle and endothelialized tissue-engineered blood vessels (eTBEVs) using primary and iPS-derived cells and assessed the response to drugs and pro-inflammatory cytokines. These models replicate the structure and key functions of the native tissue and maintain their structure and function for at least 4 weeks. These in vitro tissue systems accurately model the response to drugs. Our goal in this project is to develop clinically relevant hMPS disease models to examine rheumatoid arthritis (RA) risk for muscle dysfunction and atherosclerosis and the role of exercise in attenuating disease-associated inflammation. To meet this goal, we will expand our preliminary results to develop and validate an early atherosclerosis model that uses flow conditions promoting endothelial dysfunction, macrophage accumulation, foam cell formation, and altered vasoactivity. We will reproduce the RA phenotype in skeletal and cardiac muscle through addition of macrophages and cytokines present in RA, and demonstrate that simulated exercise conditions on muscle produce myokines that reduce inflammation in this RA model. Then, we will develop an integrated perfusion system for eTEBVs, skeletal and cardiac muscle and show that the RA model can increase macrophage accumulation in eTEBVs and cardiac bundles, and assess the response to exercise and drugs to treat atherosclerosis and inflammation. We will use CRISPR gene editing technology to generate mutations to proprotein convertase subtilisin/kexin type 9 (PCSK9) and genes that affect IL-6 shedding to assess their impact on endothelial dysfunction and foam cell formation in eTEBVs, and inflammation in skeletal and cardiac muscle bundles. We will profile cytokines and metabolites in the models with and without RA, and demonstrate that disease progression and biomarkers are reduced in the presence of common anti-inflammatory therapeutic interventions for atherosclerosis, and assess the effect of exercise. Likewise, in the RA muscle model, we will examine whether gene variants produce alterations in cytokine profiles impacting muscle function and response to exercise; these may point toward new disease-associated biomarkers and therapeutic targets. Results of this project will provide a general framework for in vitro modeling of atherosclerosis and autoimmune diseases and the role of gene variants in disease severity and drug development.

摘要